A phase I, multicenter, open-label study of oral ABL001 in patients with chronic myelogenous leukemia or Philadelphia Chromosome-positive acute lymphoblastic leukemia
The goal of this clinical research study is to find the highest tolerable dose of ABL001 taken alone in CML or Ph+ ALL patients, and ABL001 in combination with nilotinib, imatinib, or dasatinib in patients with CML. The safety of this drug taken alone and in combination with nilotinib, imatinib, or dasatinib will also be studied. This is the first study using ABL001 in humans.
Treatment Location: N/A
IRB Review and Approval Date: 07/30/2015
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: